600276 恒瑞医药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入15,761,19415.88%27,984,60522,819,78521,275,27125,905,526
减:营业总成本10,900,17411.73%21,008,00118,214,15317,747,08421,792,969
    其中:营业成本2,114,96212.90%3,848,1773,525,2483,486,6393,741,799
               财务费用(241,036)-36.94%(572,732)(478,390)(470,867)(337,956)
               资产减值损失(9,444)-159.71%(32,538)(107,217)(146,684)(13,861)
公允价值变动收益111,2641,375.22%108,631(58,257)76,50336,233
投资收益(22,158)37.28%4,279(49,157)387,365213,434
    其中:对联营企业和合营企业的投资收益(41,467)20.62%(21,581)(72,696)(62,996)(6,940)
营业利润5,158,89329.47%7,490,6324,909,9054,111,9604,664,816
利润总额5,050,93434.63%7,169,6904,667,1103,968,4924,466,309
减:所得税费用596,26484.33%832,695389,289153,351(17,718)
净利润4,454,67129.94%6,336,9954,277,8213,815,1424,484,027
减:非控股权益4,564-226.23%468(24,615)(91,233)(46,191)
股东净利润4,450,10629.67%6,336,5274,302,4363,906,3754,530,218

市场价值指针
每股收益 (元) *0.70029.63%1.0000.6800.6100.710
每股派息 (元) *----0.2000.2000.1600.160
每股净资产 (元) *8.80931.83%7.1366.3445.9295.473
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容